BCAR3

BCAR3 Full Name

breast cancer anti-estrogen resistance 3

BCAR3 Introduction

BCAR3 (breast cancer anti-estrogen resistance 3), also known as NSP2, is a cytoplasmic signaling adaptor that has emerged as an important regulator of cancer cell behavior, particularly where cell adhesion, motility, growth, and therapy resistance intersect. Rather than functioning as a classical enzyme or receptor, BCAR3 helps assemble and coordinate signaling complexes downstream of integrins and receptor tyrosine kinases. Structurally, it contains an N-terminal SH2-like domain and a C-terminal region that participates in protein–protein interactions, allowing BCAR3 to connect extracellular signals with intracellular pathways controlling the actin cytoskeleton and cell movement. This signaling role makes BCAR3 relevant to researchers investigating why tumors become more invasive or continue growing despite targeted treatment. Current evidence also places BCAR3 within broader regulatory networks involving SRC-family kinases, CAS proteins, integrin signaling, and MET/HGF signaling, supporting its potential value as a mechanistic cancer target rather than simply a marker of tumor status.

Functionally, BCAR3 is closely associated with the control of cell adhesion, cytoskeletal remodeling, migration, proliferation, and survival. Its activity can influence the formation and organization of actin-rich structures required for directional cell movement, helping cancer cells detach, migrate, and invade surrounding tissues. In breast cancer, BCAR3 has attracted particular attention because of its association with anti-estrogen resistance and aggressive tumor phenotypes. Studies in triple-negative breast cancer (TNBC) indicate that elevated BCAR3 expression is associated with tumor progression and poorer survival, while experimental depletion of BCAR3 can reduce tumor growth. Mechanistically, BCAR3 can cooperate with MET signaling to regulate proliferative and migratory responses, with the precise dependency varying according to the genetic context of the tumor. More recent work has further expanded the mechanistic picture by identifying BCAR3 as a substrate of the methyltransferase SMYD2. SMYD2-mediated methylation of BCAR3 at K334 promotes recruitment of FMNL proteins and cytoskeletal remodeling, providing a direct molecular connection between post-translational modification, cell motility, and metastatic behavior.

From a disease perspective, BCAR3 is therefore increasingly viewed as a potential biomarker and therapeutic vulnerability in aggressive cancers, although its clinical utility remains under investigation. In TNBC, increased BCAR3 expression has been detected in ductal carcinoma in situ and invasive tumors, and higher BCAR3 mRNA levels have been linked to shorter survival in patient cohorts. Experimental studies have also shown that BCAR3 supports tumor growth in vivo, while BCAR3 depletion suppresses tumor progression. Its relevance is not restricted to breast cancer: BCAR3 overexpression has been reported in head and neck squamous cell carcinoma, where it is associated with perineural invasion and unfavorable prognosis, and loss of BCAR3 reduces cancer-cell proliferation and tumor growth. The emerging SMYD2–BCAR3–FMNL axis further suggests that disrupting BCAR3-associated signaling or its regulatory modifications could represent a strategy for limiting cancer invasion and metastasis. For researchers studying BCAR3 as a target, the key challenge is to distinguish its tumor-promoting functions from context-dependent signaling roles in normal cells; nevertheless, the accumulating evidence supports continued investigation of BCAR3 in cancer progression, anti-estrogen resistance, cytoskeletal remodeling, metastasis, and precision oncology.

Alternate Names for BCAR3

BCAR3; breast cancer anti-estrogen resistance 3; breast cancer anti-estrogen resistance protein 3; NSP2; SH2D3B; novel SH2-containing protein 2; SH2 domain-containing protein 3B; dJ1033H22.2 (breast cancer anti-estrogen resistance 3); KIAA0554;

• 1.Moon DO. Deciphering the Role of BCAR3 in Cancer Progression: Gene Regulation, Signal Transduction, and Therapeutic Implications. Cancers (Basel). 2024, 16(9):1674.
  2.Arras J, et al.; Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes tumor growth and progression in triple-negative breast cancer. Am J Cancer Res. 2021, 11(10):4768-4787.